Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tenofovir exalidex
- Development stage
- Phase 1
- Lead developer
- Hepion Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Tenofovir exalidex is an orally active, liver-targeted, lipid-conjugated prodrug of tenofovir developed to treat chronic hepatitis B virus (HBV) infection. It is designed to enhance bioavailability and tissue penetration by leveraging lipid uptake mechanisms, resulting in higher concentrations in liver cells and lower systemic exposure compared to other tenofovir formulations. This targeted delivery aims to reduce the risk of renal and bone toxicities associated with traditional tenofovir therapies. Tenofovir exalidex acts as a nucleotide reverse transcriptase inhibitor, blocking viral replication by inhibiting the HBV reverse transcriptase enzyme. The drug has demonstrated potent antiviral activity against HBV in clinical studies and was also investigated for HIV infections but development for HIV has been suspended. Originally developed by Chimerix, it was further advanced by ContraVir Pharmaceuticals (now Hepion Pharmaceuticals)[3][4][6][7][8].
- Brand names
- TXL
- Other names
- Hexadecyloxypropyl-tenofovirlipid conjugate TFVLipid conjugate YTFV
02
Targets
Human immunodeficiency virus type 1 reverse transcriptaseHBV Pol (Hepatitis B virus polymerase)
Beyond the preview
Go deeper on tenofovir exalidex.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tenofovir exalidex.